Stopping GLP-1 Medications: What Happens to Your Weight

You have reached your goal weight. The active weight loss phase is done. Now comes the question that matters most: what do you do next?

Maybe you are thinking about stopping your medication entirely. Maybe you have already stopped and are watching the weight creep back up. Or maybe you are trying to decide whether to stay on something long-term, even at a lower dose.

The good news is that there is actual research data that can help you think through this decision clearly. The bad news is that the data is straightforward, and it might not be what you hoped to hear. But understanding it now, before you make a decision, is much better than learning it later.

What the STEP 4 trial showed: the most important data

In 2021, researchers published the results of a major clinical trial that tested what happens when people stop GLP-1 medication. This trial, called STEP 4^[1], is among the most directly relevant evidence for this decision.

Here is what they did: 902 adults with obesity or overweight took semaglutide during a 20-week run-in, working up to 2.4mg per week. The 803 who reached that dose were then randomized into two groups. One group continued taking semaglutide at 2.4mg per week. The other group switched to placebo, which meant they were stopping the medication, though they didn’t know which group they were in. Both groups also received lifestyle support. They were followed for another 48 weeks.

The results were clear.

At the 20-week mark, before randomization, participants had lost an average of 10.6% of their starting body weight. Over the following 48 weeks, here is what happened:

The group that continued semaglutide kept losing weight, about 7.9% more of their body weight on average.

The group that switched to placebo regained weight steadily, gaining back an average of 6.9% of their body weight over those 48 weeks. The appetite returned, and the weight came back.

A separate study, the STEP 1 trial extension, followed people who stopped semaglutide after 68 weeks of treatment. One year later, they had regained about two-thirds of the weight they had lost.^[2] The tirzepatide trial SURMOUNT-4 found the same pattern: after 36 weeks at their maximum tolerated dose (10 or 15mg), people switched to placebo regained 14.0% of their body weight over the next year, while those who continued lost a further 5.5% on average.^[3]

These are not theoretical or anecdotal findings. They come from well-designed clinical trials published in major medical journals. Results vary, and trial results describe study participants, not what will happen to you.

Why regain happens: the biology

Now that you know what happens, let’s understand why it happens. This matters because it changes how you think about the situation.

GLP-1 is a naturally occurring hormone your body produces when you eat. It does several important things: it tells your brain that you are full, it slows how fast food moves through your stomach, and it reduces the mental urge to eat. It is one of several biological signals that regulate appetite.

For many people with obesity or overweight, this appetite-signaling system is dysregulated. The brain is not receiving the fullness signals it should. The constant urge to eat is louder than it should be. This is not a character flaw or a willpower issue. It is biology.

GLP-1 medications like semaglutide amplify this signal. They turn up the volume on the “I am full” message. They make the appetite urge quieter.

When you stop the medication, that amplification disappears. The volume returns to its normal setting, which for many people is still dysregulated. The appetite signals that the medication was suppressing come back. You are not suddenly weak or unmotivated. The biological pressure is back.

This is also why the approved semaglutide and tirzepatide products for weight are labeled to reduce excess body weight and maintain that reduction long term, alongside diet and physical activity.^[4] They are designed as ongoing treatment, much like medications for blood pressure or cholesterol.

Here is the important nuance: habits you build during treatment still matter. But the trial data suggests their effect on regain is modest. In STEP 4, both groups received lifestyle support, and the group switched to placebo still regained significant weight. Biology is powerful.

Who does well after stopping

Not everyone regains all of their weight after stopping, and some people hold much of their result. Research on who does best is limited, so treat the points below as factors that may help, not predictions.

People who built lasting eating habits. If you spent your treatment phase learning to prioritize protein, reduce ultra-processed foods, and develop eating patterns that feel sustainable, you have more to fall back on than someone who relied mainly on the medication to control intake.

People who added regular resistance training and kept it up. Strength training helps preserve muscle, and many people find a regular movement practice makes maintenance easier.

People who planned the stop with their provider. Some providers step the dose down gradually before stopping rather than stopping at full dose. This is an approach some providers use, but the evidence for it is thin; the main trials compared continuing a full dose with stopping, not tapering.

None of these factors guarantee success. In the trials, most people who stopped regained a large share of the weight they had lost.

Three paths forward after reaching goal weight

If you have reached goal weight, or are considering stopping, you have three main options to think through with your provider.

Path 1: Stop completely. This works for some people. The trial data shows it does not work for most. If you choose this path with your provider, understand that weight regain is likely. If it happens, recognize it is not failure. It is biology returning. Restarting treatment or moving to a maintenance dose are both options to discuss.

Path 2: Continue your current dose. The approved products are labeled for long-term use, and in the maintenance trials, the people who kept their results stayed on their full dose. For some people, particularly those with ongoing obesity-related health conditions, staying on the medication long term is the right choice. This is between you and your provider.

Path 3: Transition to a lower maintenance dose. This is the middle path. You keep some of the appetite-signaling support the medication provides, at a lower dose. Doses below the labeled maintenance doses for weight are off-label, and lower-dose maintenance has not been tested in the major trials. If you are interested, your provider decides whether it fits and what dose makes sense based on your response and goals. See maintenance dose after goal weight for how that transition can work.

Program options to review

If you are thinking about continuing at a maintenance dose, or restarting, programs differ a lot in what they offer and how they handle maintenance. Questions worth asking before you choose one:

• Does a licensed provider review your history and decide whether a maintenance dose is appropriate, or is the dose set by a standard plan?
• Is the medication an FDA-approved brand-name product or compounded, and which pharmacy prepares it?
• How does the provider decide when to lower a dose, and what happens if your weight starts to come back?
• What is the total cost: medication, dose changes, visits, labs, shipping, membership fees, and cancellation terms? Prices vary by program and dose.
• How often will you hear from the provider, and how do you reach them with questions?

At most telehealth programs, a licensed provider decides whether a prescription is appropriate. Ask each program how its visits work where you live.

Transformation Health does not accept payment from providers. How we make money.

What to do if you have already stopped and regain is happening

If you have already stopped your medication and are watching the weight come back, you are not alone. This is very common.

What you are experiencing is not a sign that you failed or that the medication failed. It is the return of biological appetite signaling that the medication was modulating. It is normal. It is predictable. And you have options.

These are paths people commonly discuss with a provider:

Restart treatment. You may be able to return to treatment and resume active weight loss. Discuss this with a provider, because after a break, providers often restart at a lower dose and work back up rather than returning straight to your old dose.

Transition to a maintenance dose. Even if you do not want to restart full-dose treatment, a provider may consider a lower maintenance dose to help stabilize your weight. This is less intensive than active treatment, though the evidence for lower-dose maintenance is still limited.

Pursue a lifestyle-only approach with professional support. Some people choose not to continue medication. If this is your path, work with a provider, dietitian, or coach who can help you build the eating habits and movement practices that support your results. Be realistic about your odds, given the trial data above.

It is worth acting early. Raising it with a provider when you notice the first few pounds coming back gives you more options than waiting until most of your results are gone.

Should you taper off or stop abruptly?

A question that comes up frequently: if I am going to stop, should I taper down slowly or can I stop abruptly?

There is no established tapering schedule for GLP-1 medications used for weight. The FDA labels list maintenance doses, not a step-down plan, and the main trials compared continuing a full dose with switching to placebo.^[1][3][4] GLP-1 medications are not known to cause the kind of withdrawal syndrome some other medications do; the main change is that appetite returns.

Some providers step the dose down gradually before stopping, so appetite comes back in stages rather than all at once. Doses below the labeled maintenance doses are off-label, and the evidence for tapering is thin. Whether it makes sense for you is a decision for the provider who prescribes your medication.

Do not stop or change your dose on your own. Talk with your prescriber first, especially if you also take the medication for type 2 diabetes or another condition, so you have a plan for what comes next.

Key takeaways

The research is consistent. In STEP 4, the STEP 1 extension, and SURMOUNT-4, people who stopped semaglutide or tirzepatide regained a large share of the weight they had lost, while those who continued kept losing or held steady. This is not a failure of willpower. It is biology. Results vary.

You have three realistic paths to discuss with your provider: stopping completely (with the understanding that regain is likely), continuing your current dose (the approach the approved labels and the main trials support), or transitioning to a lower maintenance dose (an off-label middle ground with limited evidence).

If you have already stopped and regain is happening, raise it with a provider early. You have options.

Your provider knows your health history, your response to medication, and your goals. Make the decision with them. The goal is to find what works for your body and your life long-term, not to fit into any particular approach.

Citations

[1] Rubino D, et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.” JAMA 2021;325(14):1414-1425. https://pubmed.ncbi.nlm.nih.gov/33755728/

[2] Wilding JPH, et al. “Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.” Diabetes Obes Metab 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/

[3] Aronne LJ, et al. “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.” JAMA 2024;331(1):38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/

[4] Novo Nordisk. Wegovy (semaglutide) prescribing information, sections 1 and 2.2 (label dated 2026-06-18, accessed 2026-10-16). https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf ; Eli Lilly and Company. Zepbound (tirzepatide) prescribing information, sections 1 and 2.2 (label dated 2026-09-10, accessed 2026-10-16). https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf